SPRTN抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P09403(SPRTN Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P09403(SPRTN Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

SPRTN (also known as DVC1) is a metalloprotease critical for maintaining genome stability by resolving DNA-protein crosslinks (DPCs) during DNA replication and repair. DPCs are toxic lesions that block replication forks and transcription machinery, often caused by environmental agents (e.g., formaldehyde) or endogenous metabolites. SPRTN recognizes and cleaves covalently trapped proteins on DNA, enabling their proteasomal degradation. Mutations in SPRTN are linked to Ruijs-Aalfs syndrome, a progeroid disorder characterized by genomic instability, accelerated aging, and cancer predisposition.

SPRTN antibodies are essential tools for studying its role in DNA repair mechanisms. They are widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to analyze SPRTN expression, localization, and interactions. Research using these antibodies has revealed SPRTN's recruitment to replication stress sites, its regulation by ubiquitination, and functional crosstalk with Fanconi anemia pathway proteins. Commercial SPRTN antibodies are typically validated in knockout cell lines to ensure specificity. Understanding SPRTN's molecular functions through antibody-based studies holds therapeutic potential for targeting DPC-related diseases, including cancer and premature aging syndromes.